Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT00508274
- Locations
- 🇭🇰
Novartis Investigative Site, Shatin, Hong Kong
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
- Conditions
- Breast CancerMetastatic Breast CancerAdvanced Breast CancerHER2/Neu-positive Breast Cancer
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 11
- Registration Number
- NCT00496366
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT00495872
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8382
- Registration Number
- NCT00490139
- Locations
- 🇬🇧
Novartis Investigative Site, Worthing, United Kingdom
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
- Conditions
- Head and Neck CancersHead and Neck CancerCarcinoma, Squamous Cell
- Interventions
- Drug: LapatinibProcedure: Radiotherapy (radiation)Device: G.E. Healthcare 1.5T MR, systems revision 12.0 M5Device: DCE-MRI
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Quynh-Thu Le
- Target Recruit Count
- 17
- Registration Number
- NCT00490061
- Locations
- 🇺🇸
Beth Israel, New York, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸University of Wisconsin Cancer Center, Madison, Wisconsin, United States
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
- Conditions
- Invasive Breast Cancer
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 529
- Registration Number
- NCT00486668
- Locations
- 🇺🇸
CCOP, William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸CCOP, Hematology-Oncology Associates of CNY, Syracuse, New York, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
- Conditions
- Neoplasms, Gastrointestinal Tract
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 273
- Registration Number
- NCT00486954
- Locations
- 🇨🇳
GSK Investigational Site, Tau-Yuan County, Taiwan
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
- Conditions
- Relapsed Breast CancerNeoplasms, Breast
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00479856
- Locations
- 🇺🇸
GSK Investigational Site, Fairfax, Virginia, United States
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
- Conditions
- Neoplasms, BreastMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 51
- Registration Number
- NCT00477464
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
- Conditions
- Breast CancerBrain Metastases
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 35
- Registration Number
- NCT00470847
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.